This is an attractive strategy for 35–40% of Rett syndrome patients who have nonsense mutations in MECP2 that result in premature stop codons, which inhibit normal full-length protein expression (Neul et al. 2008). This evidence concerns the gene MECP2 and atypical Rett syndrome.